Summary & Overview
HCPCS G0482: Definitive Mass-Spectrometry Drug Test, 15–21 Drug Classes
Headline: HCPCS Level II code G0482 Defines High-Specificity Mass-Spectrometry Drug Testing
HCPCS Level II code G0482 represents definitive drug testing performed using high-specificity analytical methods such as GC/MS or LC/MS with stable isotope/internal standards and method-specific calibration. The code covers qualitative or quantitative testing across 15–21 drug classes, includes specimen validity testing, and is reported on a per-day basis. This test type is central to forensic, clinical toxicology, pain management monitoring, and substance use disorder programs because of its ability to distinguish structural isomers and provide definitive identification where immunoassays are insufficient.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical and laboratory context for G0482, typical sites of service, and which elements of testing (stable isotope standards, calibration, matrix-matched QC, and specimen validity testing) are required to meet the code definition. The publication also summarizes common modifiers and administrative details provided in the source, and points to where national policy and reimbursement considerations typically intersect with high-complexity toxicology services. Data not available in the input are noted where applicable. The content is intended to support billing, coding, and policy teams in understanding the scope and clinical intent of G0482 at a national level.
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient enrolled in an outpatient substance use disorder program presents for routine monitoring and compliance testing. The clinician orders a definitive multi-drug confirmatory panel after a presumptive positive immunoassay screen or as part of a random compliance check for opioid treatment. The laboratory collects a urine specimen, performs specimen validity testing, and runs definitive testing using gas chromatography–mass spectrometry (GC/MS) or liquid chromatography–mass spectrometry (LC/MS) methods with stable isotope internal standards and matrix-matched quality controls. Results report identification and, when clinically indicated, quantitation of 15–21 drug classes and relevant metabolites. The laboratory transmits results to the ordering clinician for care management decisions, such as treatment adjustment, counseling, or referral for higher level of care.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the laboratory professional interpretation component separate from technical testing, if applicable under local rules. |
52 | Reduced services | Use when the definitive test was partially performed or a limited panel was completed at reduced scope. |